tirzepatide hydroxocobalamin Troubling Findings in Study of GLP-1 Compounders Tirzepatide + B12 (10mg–40mg) |

According to FAIR Health, prescriptions for GLP-1 drugs to treat overweight or obesity rose 587% from 2019 to 2024

But that does not mean timing is irrelevant

Statistical analysis was performed ANOVA (to analyse the difference between the means of more than two groups) or Students t test (to compare the means of specifically two groups), after normality was assessed by a Shapiro-Wilk test

Reductions of up to approximately 10% were observed in certain biomarkers, although these effects did not translate into measurable clinical benefit within the trial timeframe

Clinical trials have demonstrated its effectiveness in lowering HbA1c levels and promoting weight loss, with a safety profile comparable to existing GLP-1 therapies

Physical performance